Summary.-Monoclonal antibodies against 2 human lung carcinoma cell lines (E14 and BEN) were prepared by production and cloning of somatic cell hybrids between the murine myeloma NS1, and spleens from E14-and BEN-immune BALB/c mice. Approximately 2000 hybrid culture supernatants were screened for antibody simultaneously against the immunizing cell line and lung fibroblasts (573 Lu) using a radiolabelled Protein A binding assay. Although the vast majority secreted antibodies which recognized species-specific antigens, a few supernatants showed marked differential reactivity against E14 or BEN. These were cloned and subsequently tested against a panel of up to 25 human cell lines originating from different neoplastic and non-neoplastic tissues. Two anti-E14 clones (3E19.8 and 4EAB3.7) displayed preferential activity against lung cancer cell lines, but a low level of reactivity was also detectable with cell lines of different tissue provenance. The antibodies of 3 anti-BEN clones (7B3.5, 7B5.4, 7B17.7) likewise recognized antigens present to a higher density on lung cancer cell lines but were also reactive (to a variable extent for the different clones) with a diversity of other tumour cell lines. The antibodies of 2 further clones were exceptional in so far as one (7BC9.1) reacted only with BEN and WIDR (colorectal cancer) cells, while another (7B24.4) reacted, with apparent exclusivity, against BEN cells. With the exception of the latter, the distinction in antigen expression between many of the cell lines was quantitative rather than qualitative and the emergent picture is one of random expression of individual determinants on several disparate types of cancer cells, rather than restriction to cells of a given morphological type or histogenic derivation.
SINCE the description by Kohler & Milstein (1975) of somatic cell-hybridization as a means of generating monoclonal antibodies to cell-surface antigens, a considerable body of data has already accumulated on the expression of such antigens on human tumours. Earlier claims of tissue-site specificity and even of unique tumour specificity for some neoplasms (e.g. malignant melanoma, colorectal carcinoma, neuroblastoma (Koprowski et al., 1978; Yeh et al., 1979; Kennett & Gilbert, 1979; Carrel et al., 1980) have more recently given place to reports of greater complexity in antigen distribution, including, for example, apparently random expression not associated with any particular tumour type (Embleton et al., 1981) , and cross-reactivity between different tumours (malignant melanoma and brain) of common embryological derivation (Liao et al., 1981) .
The evocation of monoclonal antibodies to human carcinoma of lung has received limited attention to date. Sikora & Wright (1981) generated antibodies from interspecies hybrids of hilar and bronchial lymph nodes, with rat or mouse myeloma cells, which were preferentially reactive with lung tumour cell membranes, in comparison with those of normal lung tissue. Other investigators, using established cell lines as immunogens, have developed intraspecies hybrids producing antibodies recognizing antigens of variable distribution on lung and other cancer cells (Kasai et al., 1981; Cuttitta et al., 1981) .
In this study the distribution of antigens expressed on cultured lung cancer cells and on tumours of different provenance and histology was investigated by the production of monoclonal antibodies to two well-characterized cell lines (E14 and BEN) originating from squamous cell carcinoma of the bronchus (Fischer & Vetterlein, 1977; Ellison et al., 1975; Ham etal., 1980; Lumsdenetal., 1980) .
METHODS AND MATERIALS
Ce118.-The parental myeloma line used in these experiments was P3-NSI-I-Ag4-1 (NS1) (Flow Laboratories, Irvine, Scotland) . Cells were grown in suspension in DMEM supplemented with 10% foetal bovine serum (FBS) and 1 mM pyruvate (Flow Labs) and subcultured at 2 x weekly intervals. Frozen stocks were maintained at -70TC in 90% newborn calf serum (NBCS) and 10% dimethyl sulphoxide (Sigma Chemical Co., U.S.A.). Cells used in fusion experiments were harvested during the logarithmic phase of growth, washed x 2 with serum-free DMEM and routinely checked for aminopterin sensitivity before fusion.
The IgG1 secreting mouse myeloma line P3-X63-Ag8 (X63) was maintained as for NS1, as a source of control murine antibody-containing supernates in the binding assays.
Various human cell lines of different provenance and morphology were used in this study (Table) . These were routinely maintained in DMEM plus 10% FBS (Chen, 1977; Boyle et al., 1981 Confluent monolayers were obtained between 2 and 5 days depending on the input number and these were fixed with glutaraldehyde (0 25% in PBS) (BDH Chemicals Ltd, U.K.)
for 10 min at room temperature to improve adherence, washed and maintained at 4°C under PBS containing BSA (for <3 days) before deployment in the binding assay. This was carried out essentially as for the suspension assay except that centrifugation was obviated and coverslips were transferred direct to LP3 tubes for counting. Comparison of data obtained with the same targets in suspension and monolayer assays indicated that they could be used interchangeably. Suspensions were used for specificity analysis and the monolayer modification for screening where large numbers of supernates were involved.
RESULTS

Monoclonal antibodies against El 4
Supernates of 46/485 (9.5%) wells screened from 10 x 96 well microtitre plates of one fusion (3E) contained antibodies reactive with E14 cells, the majority of which were also reactive with 573Lu cells.
Cells generating supernatants with proportionately greater anti-E1 4 reactivity as well as a number equally reactive with 573Lu cells were cloned. Some hybrids which showed only low reactivity in the primary assays, failed to generate a stable antibody-producing hybrid (presumably on account of instability of the original antibody-producing cells). Fig. 1 shows the reactivity of different 3E hybridoma lines against various targets in suspension assays. 3E10.2 and 3E22.1 antibodies reacted with 2/3 lung carcinoma cell lines, a colorectal carcinoma cell line (WIDR) as well as the normal 573Lu line, while the 3E11.5 antibody reacted with all cell lines against which it was tested. The 3E14.5 antibody also reacted with all cell lines although binding was greater with the 5 epithelial carcinoma lines (especially E14) than with the lung fibroblast lines. The 3E19.8 antibody reacted most strongly with the carcinoma cell lines of lung origin (again especially While the majority of these were polyspecific (i.e. reactive against 573Lu in addition to E14/BEN), or (in one instance) reactive with serum components, one supernate (designated 7BC9) was identified as of potential importance in that it appeared to discriminate between BEN and E14 cells.
Supernatants from several cloned lines resulting from this fusion (7B and 7BC hybrid lines) were tested in suspension for reactivity against the cell line panel. Fig. 3 shows the binding data for 3 monoclonal antibodies which showed a more varied pattern of reactivity. The 7B3.5 antibody reacted with all 5 lung carcinoma lines tested, but with only one of 4 fibroblastic lung lines. It also bound to 1/2 colorectal carcinoma lines (HT29), 2/2 osteosarcoma lines (791T and 788T) and single lines derived from malignant n,elanoma (RPMI Two monoclonal antibodies were produced which recognized a target antigen of very restricted distribution. The 7BC9.1 antibody bound only to the immunizing lung carcinoma BEN and at a much lower degree to the colorectal carcinoma cell line, WIDR (Noguchi et al., 1979) . Also, the 7B24.4 antibody recognized a determinant expressed at high density only on the immunizing BEN cell line but which was undetectable on 12 other human cell lines tested (Fig. 4) . The specificity of these latter antibodies was thus greater than any other generated in the study.
None of the antibodies showing any selectivity for the human cell lines was reactive with sheep or human red blood cells (of whatever major group).
DISCUSSION
From all fusions with spleens from mice immunized with E14 cells, the frequency of monoclonal antibodies reactive with cell-surface antigens of restricted distribution was low. Widely cross-reacting, species-specific antigens were the immunodominant determinants giving rise to these antibodies, the elicitation of which was largely independent of the immunization protocol. Even coating E14 cells with murine antiserum against the lung fibroblast 573Lu line for the final i.v. injection, a procedure designed to mask the response to unwanted determinants (Kennett & Gilbert, 1979) (Irie et al., 1974; Embleton & Jype, 1978) . However, it is possible that the antibody reacts with antigens acquired by some cells as a consequence of in vitro passage, rather than with antigens associated with the transformed state. For this reason, prospective testing of antibodies by immunohistology should be used to amplify binding assays against select cell lines (Finan et al., 1982) . Even so it appears that this antibody reacts with a determinant expressed ony by certain human carcinoma cells of different origin.
Similar overall, but individually variable patterns of reactivity were observed for clones producing anti-BEN antibodies (7B3.5, 7B5.4, 7B17.7). The target antigens recognized by these antibodies again appear to be present at a higher density on most (Kasai et al., 1981; Cuttitta et al., 1981) . To this extent, reagents of the type generated in this study offer potentially a productive means of delineating the complex antigenic profiles of human lung cancer. Implicit in our findings and those of other investigators, however, is the notion that the phenotyping of human cancers for diagnostic and therapeutic exploitation will probably entail the generation of panels of mouse monoclonals recognizing many different determinants.
